Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia.
Kazuharu KamachiHiroshi UreshinoTatsuro WatanabeNao Yoshida-SakaiYuki Fukuda-KurahashiKazunori KawazoeToshimi HoshikoYuta YamamotoYuki KurahashiShinya KimuraPublished in: Cancer research communications (2023)
, suggesting that the combination of OR2100 plus Ven is a promising candidate oral therapy for AML.